Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Merit Care Hospital
1194
mi
from 98109
Fargo, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Merit Care Hospital
1194
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Altru Cancer Center
1169
mi
from 98109
Grand Forks, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Altru Cancer Center
1169
mi
from 98109
Grand Forks, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Toledo Community Hospital
1929
mi
from 98109
Toledo, OH
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Toledo Community Hospital
1929
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Oklahoma
1564
mi
from 98109
Tulsa, OK
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Oklahoma
1564
mi
from 98109
Tulsa, OK
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Geisinger Clinic and Medical Center
2273
mi
from 98109
Danville, PA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Geisinger Clinic and Medical Center
2273
mi
from 98109
Danville, PA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Rapid City Regional Hospital
949
mi
from 98109
Rapid City, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Rapid City Regional Hospital
949
mi
from 98109
Rapid City, SD
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Sioux Community Cancer Consortium
1263
mi
from 98109
Sioux Falls, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Sioux Community Cancer Consortium
1263
mi
from 98109
Sioux Falls, SD
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
James Berenson, MD, Inc
957
mi
from 98109
West Hollywood, CA
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
James Berenson, MD, Inc
957
mi
from 98109
West Hollywood, CA
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
H. Lee Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
H. Lee Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Northwestern University
1733
mi
from 98109
Chicago, IL
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Research Facility
2401
mi
from 98109
New York, NY
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Research Facility
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Rigshospitalet
4835
mi
from 98109
Copenhagen,
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Rigshospitalet
4835
mi
from 98109
Copenhagen,
Click here to add this to my saved trials
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Oncotherapeutics
957
mi
from 98109
West Hollywood, CA
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Oncotherapeutics
957
mi
from 98109
West Hollywood, CA
Click here to add this to my saved trials
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Center for Cancer & Blood Disorders
2314
mi
from 98109
Bethesda, MD
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Center for Cancer & Blood Disorders
2314
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Baylor University Medical Center
1681
mi
from 98109
Dallas, TX
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Baylor University Medical Center
1681
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
UCLA's Jonsson Comprehensive Cancer Center
962
mi
from 98109
Los Angeles, CA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
UCLA's Jonsson Comprehensive Cancer Center
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Children's Hospital of Orange County
984
mi
from 98109
Orange, CA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Children's Hospital of Orange County
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
The Children's Hospital, B115, University of Colorado Health Sciences Center
1027
mi
from 98109
Aurora, CO
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
The Children's Hospital, B115, University of Colorado Health Sciences Center
1027
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
1731
mi
from 98109
Chicago, IL
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
1731
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
1723
mi
from 98109
Maywood, IL
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
1723
mi
from 98109
Maywood, IL
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
The Cancer Center, Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
The Cancer Center, Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Cornell University, Joan & Sanford I. Weill Medical College
2402
mi
from 98109
New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Cornell University, Joan & Sanford I. Weill Medical College
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Steven and Alexandra Cohen Children's Medical Center of New York
2401
mi
from 98109
New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Steven and Alexandra Cohen Children's Medical Center of New York
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Mount Sinai Medical Center
2402
mi
from 98109
One Gustave L Levy Place, BOX 1410, New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Mount Sinai Medical Center
2402
mi
from 98109
One Gustave L Levy Place, BOX 1410, New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Western Pennsylvania Hospital
2134
mi
from 98109
Pittsburgh, PA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Western Pennsylvania Hospital
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
University of Pittsburgh Cancer Institute/UPMC Cancer Centers
2132
mi
from 98109
Pittsburgh, PA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
University of Pittsburgh Cancer Institute/UPMC Cancer Centers
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Texas Transplant Institute
1780
mi
from 98109
San Antonio, TX
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Texas Transplant Institute
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
University of Virginia, Hematopoietic Stem Cell Transplant Program
2284
mi
from 98109
West Complex 1300 Jefferson Park Av, Charlottesville, VA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
University of Virginia, Hematopoietic Stem Cell Transplant Program
2284
mi
from 98109
West Complex 1300 Jefferson Park Av, Charlottesville, VA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders
1687
mi
from 98109
Milwaukee, WI
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program
1681
mi
from 98109
Milwaukee, WI
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Szent Laszlo & Szent Istvan Hospital
5465
mi
from 98109
Budapest,
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Szent Laszlo & Szent Istvan Hospital
5465
mi
from 98109
Budapest,
Click here to add this to my saved trials
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Phase II Trial of Tacrolimus and Rapamycin vs. Tacrolimus and Methotrexate as GVHD Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  7/10/2015
H.Lee Moffitt Cancer center
2522
mi
from 98109
Tampa, FL
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Phase II Trial of Tacrolimus and Rapamycin vs. Tacrolimus and Methotrexate as GVHD Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 7/10/2015
H.Lee Moffitt Cancer center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Status: Enrolling
Updated:  7/10/2015
Children's Hospital Oakland
677
mi
from 98109
Oakland, CA
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Status: Enrolling
Updated: 7/10/2015
Children's Hospital Oakland
677
mi
from 98109
Oakland, CA
Click here to add this to my saved trials
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Status: Enrolling
Updated:  7/10/2015
Children's Hospital Boston
2484
mi
from 98109
Boston, MA
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Status: Enrolling
Updated: 7/10/2015
Children's Hospital Boston
2484
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Status: Enrolling
Updated:  7/10/2015
Hospital for Sick Children
2065
mi
from 98109
Toronto,
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Status: Enrolling
Updated: 7/10/2015
Hospital for Sick Children
2065
mi
from 98109
Toronto,
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Cryoablation for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  7/13/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Cryoablation for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 7/13/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Cryoablation for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  7/13/2015
Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Cryoablation for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 7/13/2015
Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Cryoablation for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  7/13/2015
University of British Columbia
119
mi
from 98109
Vancouver,
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Cryoablation for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 7/13/2015
University of British Columbia
119
mi
from 98109
Vancouver,
Click here to add this to my saved trials
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Status: Enrolling
Updated:  7/13/2015
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
Status: Enrolling
Updated: 7/13/2015
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/14/2015
Yale University
2432
mi
from 98109
New Haven, CT
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/14/2015
Yale University
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
984
mi
from 98109
Orange, CA
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
626
mi
from 98109
Sacramento, CA
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
626
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from 98109
East Lansing, MI
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from 98109
East Lansing, MI
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
7014
mi
from 98109
Bahia Blanca,
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
7014
mi
from 98109
Bahia Blanca,
Click here to add this to my saved trials
DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy
Diffusion Tensor Imaging of the Brain and Cervical Spine: Evaluation of Reproducibility in Normal Subjects and Diagnostic Utility in Patients With Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  7/14/2015
Center for Systems Imaging (CSI), Emory University
2179
mi
from 98109
Atlanta, GA
DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy
Diffusion Tensor Imaging of the Brain and Cervical Spine: Evaluation of Reproducibility in Normal Subjects and Diagnostic Utility in Patients With Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 7/14/2015
Center for Systems Imaging (CSI), Emory University
2179
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials